Analysts Highlight Estrella's ARTEMIS® Platform as a Game Changer D. Boral Capital has initiated coverage on Estrella Immunopharma with a $16 price target, emphasizing the ARTEMIS® T-cell platform's innovation. EB103, currently in Phase I/II trials, aims to treat relapsed blood cancers. However, a 30% success probability and conflicts of interest in the analysis raise questions for investors.34